Login to Your Account

Adaptimmune's immunotherapy fits GSK to a 'T' in expanded deal

By Marie Powers
News Editor

Tuesday, February 2, 2016

Glaxosmithkline plc expanded the terms and sweetened the economics of its strategic collaboration and licensing agreement with Adaptimmune Therapeutics plc for a T-cell receptor engineered cancer immunotherapy program initially targeting NY-ESO-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription